Share This Page
Drug Price Trends for COTEMPLA XR-ODT
✉ Email this page to a colleague
Average Pharmacy Cost for COTEMPLA XR-ODT
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| COTEMPLA XR-ODT 25.9 MG TABLET | 70165-0300-30 | 17.10725 | EACH | 2025-04-01 |
| COTEMPLA XR-ODT 17.3 MG TABLET | 70165-0200-30 | 17.14322 | EACH | 2025-04-01 |
| COTEMPLA XR-ODT 8.6 MG TABLET | 70165-0100-30 | 17.14420 | EACH | 2025-04-01 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Cotempla XR-ODT
Overview of Cotempla XR-ODT
Cotempla XR-ODT, developed by Neos Therapeutics and now part of Aytu BioPharma, is an extended-release oral disintegrating tablet containing methylphenidate, a central nervous system (CNS) stimulant. It is primarily used to treat Attention Deficit Hyperactivity Disorder (ADHD)[2].
Market Performance and Revenue
Current Revenue and Growth
In the fiscal year 2024, the ADHD Portfolio of Aytu BioPharma, which includes Cotempla XR-ODT and Adzenys XR-ODT, saw a significant increase in net revenue. The portfolio's net revenue grew by 23% to $57.8 million compared to $46.9 million in fiscal 2023[4].
Segment Performance
The Rx Segment, which includes Cotempla XR-ODT, contributed substantially to Aytu BioPharma's revenue. The segment's net revenue was $65.2 million for the full year of fiscal 2024, although it was slightly lower than the $73.8 million in the prior year period due to changes in the Pediatric Portfolio[4].
Promotional Activities and Market Reach
Physician Engagement
Cotempla XR-ODT has been actively promoted through various channels, including sales rep detailing, physician education, and paid speaking engagements. In 2019, over 13,000 paid interactions across 4,500 physicians were recorded, indicating a robust promotional strategy[1].
Comparative Analysis
The promotional activities of Cotempla XR-ODT are benchmarked against its peers in the ADHD market. The drug's depth of coverage varies within key specialties such as Pediatric Medicine, Psychiatry, and Family Medicine, and it compares favorably with its peers in terms of physician engagement[1].
Pricing and Cost Analysis
Retail Pricing
The cost of Cotempla XR-ODT varies based on the dosage and pharmacy. For a 30-tablet supply, the price ranges from approximately $549.94 for the 8.6 mg/24 hr, 17.3 mg/24 hr, and 25.9 mg/24 hr formulations. This pricing is for cash-paying customers and does not reflect insurance-covered costs[2].
Discount Programs
Patients can benefit from discount programs such as the Drugs.com Discount Card, which can save up to 80% on prescription medicines. This card is accepted at most U.S. pharmacies and can significantly reduce the out-of-pocket cost for Cotempla XR-ODT[2].
Market Trends and Projections
Global ADHD Market
The global ADHD market was valued at USD 15.8 billion in 2023 and is projected to grow at a Compound Annual Growth Rate (CAGR) of over 5.1% from 2024 to 2032, reaching an estimated value of USD 24.6 billion by 2032[3].
Specific Projections for Cotempla XR-ODT
While specific 5-year forecasts for Cotempla XR-ODT are not detailed, the overall growth in the ADHD market and the drug's increasing revenue suggest a positive outlook. Aytu BioPharma expects continued growth in the Rx Segment, driven by prescription growth and the unique benefits of their commercial platform, including transparent and predictable drug pricing[4].
Challenges and Opportunities
Market Competition
Cotempla XR-ODT operates in a competitive ADHD market with several other extended-release formulations such as Adhansia XR, Adzenys XR, and Vyvanse. The drug's success is partly dependent on its ability to differentiate itself through effective promotional activities and patient-centric programs[1].
Regulatory and Economic Factors
Changes in payor coverage and market supply chain normalization can impact revenue. For instance, the ADHD Portfolio experienced a 13% decrease in net revenue in Q4 fiscal 2024 due to these factors. However, the company's strategic focus on driving prescription growth and leveraging its commercial platform is expected to mitigate such challenges[4].
Key Takeaways
- Revenue Growth: Cotempla XR-ODT has seen significant revenue growth, with a 23% increase in the ADHD Portfolio's net revenue in fiscal 2024.
- Promotional Activities: The drug is actively promoted through various channels, engaging a substantial number of physicians.
- Pricing: The retail price for Cotempla XR-ODT is around $549.94 for a 30-tablet supply, with potential savings through discount programs.
- Market Trends: The global ADHD market is projected to grow at a CAGR of over 5.1% from 2024 to 2032.
- Challenges and Opportunities: The drug faces competition and regulatory challenges but benefits from Aytu BioPharma's strategic focus on prescription growth and patient-centric programs.
FAQs
Q: What is the current retail price of Cotempla XR-ODT?
A: The current retail price for a 30-tablet supply of Cotempla XR-ODT is approximately $549.94, depending on the dosage and pharmacy.
Q: How has the revenue of Cotempla XR-ODT performed in recent years?
A: The ADHD Portfolio, which includes Cotempla XR-ODT, saw a 23% increase in net revenue to $57.8 million in fiscal 2024 compared to fiscal 2023.
Q: What promotional activities are used to market Cotempla XR-ODT?
A: The drug is promoted through sales rep detailing, physician education, and paid speaking engagements.
Q: How does the pricing of Cotempla XR-ODT compare to other ADHD medications?
A: While specific comparisons are not detailed, Cotempla XR-ODT's pricing is competitive within the ADHD market, with potential savings through discount programs.
Q: What are the projected growth trends for the ADHD market?
A: The global ADHD market is projected to grow at a CAGR of over 5.1% from 2024 to 2032, reaching an estimated value of USD 24.6 billion by 2032.
Sources:
- MDDetails: Cotempla XR-ODT 2019 U.S. PROMOTIONAL AUDIT REPORT.
- Drugs.com: Cotempla XR-ODT Prices, Coupons, Copay Cards & Patient Assistance.
- GMI Insights: Attention Deficit Hyperactivity Disorder Market Share, 2024-2032.
- BioSpace: Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results.
More… ↓
